LYMTACs are heterobifunctional small molecules that take advantage of lysosomal membrane proteins to degrade membrane targets via relocalization and lysosomal degradation, offering a modular approach to drug otherwise intractable membrane proteins.
- Dhanusha A. Nalawansha
- Georgios Mazis
- Patrick Ryan Potts
